2017
DOI: 10.1016/j.jconrel.2017.02.022
|View full text |Cite
|
Sign up to set email alerts
|

Solvent removal precipitation based in situ forming implant for controlled drug delivery in periodontitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
17
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 27 publications
(17 citation statements)
references
References 47 publications
0
17
0
Order By: Relevance
“…At present, although ISFSs have been widely developed for the delivery of various small molecular/macromolecular hydrophilic/hydrophobic drugs at a wide spectrum of clinical conditions (Thakur et al, 2014;Juvekar & Kathpalia, 2017), there are still few reports involving their applications in bioactive PSs. In general, it is challengeable to achieve the zero-order controlled release of PSs from ISFSs in terms of hydrophilicity and the short plasma half-life of most PSs.…”
Section: In Situ Forming Systems (Isfss)mentioning
confidence: 99%
“…At present, although ISFSs have been widely developed for the delivery of various small molecular/macromolecular hydrophilic/hydrophobic drugs at a wide spectrum of clinical conditions (Thakur et al, 2014;Juvekar & Kathpalia, 2017), there are still few reports involving their applications in bioactive PSs. In general, it is challengeable to achieve the zero-order controlled release of PSs from ISFSs in terms of hydrophilicity and the short plasma half-life of most PSs.…”
Section: In Situ Forming Systems (Isfss)mentioning
confidence: 99%
“…This type of formulation is presently known as Atrigel technology, and its principles are utilized in several commercially available ISFIs. Examples of marketed products are Eligard and Lupron Depot, subcutaneous depots for the treatment of prostate cancer with controlled release of leuprolide acetate (45 mg) over 6 months, and Atridox delivering doxycycline (50 mg) to periodontal pocket in the treatment of chronic adult periodontal infections for about 21 days …”
Section: Introductionmentioning
confidence: 99%
“…Doxycycline hyclate (DOXY) is a member of this group of drugs, with bacteriostatic activity against both gram‐negative and gram‐positive bacteria. Furthermore, DOXY inhibits activity of excessive collagenase (matrix metalloproteinase)—enzyme associated with increased severity of periodontal disease . Since DOXY is already in use in commercial systems for local periodontal therapy, it was chosen as a model drug in our studies.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations